Currently, the FDA has approved multiple CAR-T cell products targeting CD19 or B-cell maturation antigen (BCMA) for clinical trials and for treating relapsed/refractory B-cell malignancies (r/r B-ALL) and multiple myeloma [3]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.